Achillion Shareholders Approve Agreement to be Acquired by Alexion
19 déc. 2019 09h24 HE
|
Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
09 déc. 2019 10h00 HE
|
Achillion Pharmaceuticals, Inc.
– 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial...
European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor
19 nov. 2019 07h30 HE
|
Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Announces Clearance of Investigational New Drug Application for ACH-5228
11 nov. 2019 07h30 HE
|
Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update
07 nov. 2019 07h30 HE
|
Achillion Pharmaceuticals, Inc.
– Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of...
Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting
06 nov. 2019 09h07 HE
|
Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
26 sept. 2019 08h32 HE
|
Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria
25 sept. 2019 07h00 HE
|
Achillion Pharmaceuticals, Inc.
– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion...
Achillion to Present at the Baird 2019 Global Healthcare Conference
29 août 2019 17h00 HE
|
Achillion Pharmaceuticals, Inc.
BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08 août 2019 07h30 HE
|
Achillion Pharmaceuticals, Inc.
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – ...